Workday Stock Retreats As Guidance Overshadows Solid Quarter Workday shares are trading lower Wednesday. The company fourth-quarter financial results on Tuesday after the market closed.
Prediction: Rivian Stock Is a Buy Before 2027 Rivian is investing heavily in artificial intelligence (AI).
Cava Stock Jumps After Q4 Double Beat CAVA Group shares are trading higher after the company reported better-than-expected Q4 financial results on Tuesday after the market closed.
RiverFront Sells 1.2 Million Shares of iShares MSCI Europe Financials ETF The iShares MSCI Europe Financials ETF tracks leading European banks, insurers, and asset managers with a passive, diversified approach.
Why Did INBS Stock Jump 11% In Pre-Market Today? The company announced the first shipment of its Intelligent Fingerprinting Drug Screening Readers, produced in collaboration with Syrma Johari MedTech.
Ozempic Price War - Novo Nordisk Slashes Prices By 50% Novo Nordisk plans up to 50% U.S. price cuts on Wegovy, Ozempic, and Rybelsus by 2027, sending shares lower in premarket trade.
Bitcoin Jumps 5% To $66,000: What Is Going On? Bitcoin (CRYPTO: BTC) is back above $66,000 on renewed ETF inflows, with on-chain data suggesting the asset may have meaningful upside if correlations normalize.
LUMN Stock Climbs 5% Pre-Market – What’s The Anthropic Connection? The company outlined several multi-year financial goals, including expansion of EBITDA margins to the mid-30% range by 2030.
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate With 40% short interest and rising hedge fund buying, ImmunityBio's explosive rally may be entering its most volatile phase yet.
The Market Awaits Nvidia, But This Data Center Builder Already Soars On Earnings Data center builder Everus Construction is already up around 22% in the 2026 stock market and is roaring higher on earnings.
IBM Faces Worst Month Since 1992 — Is Anthropic The New Dot-Com Moment? IBM stock is down 25% in its worst month since 1992 after an AI-driven COBOL threat. Is this panic justified — or a rare buying opportunity?
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans Charles River to sell CDMO, Cell Solutions, and European assets, raise 2026 earnings outlook as shares trade near 52-week lows.
A Beginner-Friendly ETF Portfolio That Requires Almost No Maintenance A well-constructed portfolio doesn't need to include dozens of stocks and ETFs. You can have everything you need with just these three funds.
